Singapore, July 9 -- The Health Sciences Authority received information related to the study titled 'Phase Ib/II Study of Tislelizumab in Combination with Bevacizumab and Capecitabine in Advanced Soli... Read More
Singapore, July 9 -- The Health Sciences Authority received information related to the study titled 'A Phase 1, Investigator- and Participant-Blinded, Placebo-Controlled, Randomized, Multiple-Dose Stu... Read More
Singapore, July 9 -- The Health Sciences Authority received information related to the study titled 'A Phase 1, Multicenter, Open-Label, First-in-Human Study to Evaluate the Safety, Tolerability, Phar... Read More
Singapore, July 9 -- The Health Sciences Authority received information related to the study titled 'A Phase 1 randomized, double-blind, placebo-controlled, single-ascending-dose study investigating t... Read More
Singapore, July 9 -- The Health Sciences Authority received information related to the study titled 'A Multinational, Multicenter Study With an Open-Label Phase 1b and a Randomized, Double-Blind, Plac... Read More
Singapore, July 9 -- The Health Sciences Authority received information related to the study titled 'A multicenter, randomized, double-blind, placebo-controlled Phase 2 study to investigate the effica... Read More
Singapore, July 9 -- The Health Sciences Authority received information related to the study titled 'A Global, Multicenter, Prospective, Controlled, Open-Label Pivotal Study of Iodofalan (131I) Soluti... Read More
Singapore, July 9 -- The Health Sciences Authority received information related to the study titled 'RASolute 303: A Phase 3 Global, Multicenter, Open-label, Randomized, 3-Arm Study of Daraxonrasib Mo... Read More
Singapore, July 9 -- The Health Sciences Authority received information related to the study titled 'N-Acetylcysteine or Erdosteine for Exacerbations of Chronic Obstructive Pulmonary Disease (NEX COPD... Read More
Singapore, July 9 -- The Health Sciences Authority received information related to the study titled 'A Multicenter, Multi-Part, Phase 1/2 Study of EIK1005 as Monotherapy and in Combination with Pembro... Read More